Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholinergic function and Alzheimer's disease.

Ezio Giacobini1

  • 1Hôpital Universitaire de Geriatrie, Route de Mon Idée, CH-1226 Thônex, Genève, Switzerland. ezio.giacobini@hcuge.ch

International Journal of Geriatric Psychiatry
|September 16, 2003
PubMed
Summary

Alzheimer's disease (AD) involves cholinergic deficits. Current treatments targeting acetylcholinesterase (AChE) may be enhanced by exploring butyrylcholinesterase (BuChE) inhibition and combination therapies for better outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A brief history of the CNS cholinergic transmission.

Handbook of clinical neurology·2025
Same author

Reimagining cholinergic therapy for Alzheimer's disease.

Brain : a journal of neurology·2022
Same author

Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery.

Neuropharmacology·2020
Same author

Sex differences in Alzheimer disease - the gateway to precision medicine.

Nature reviews. Neurology·2018
Same author

Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors.

Current Alzheimer research·2018
Same author

The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Brain : a journal of neurology·2018

Area of Science:

  • Neuroscience
  • Pharmacology
  • Gerontology

Background:

  • Cholinergic dysfunction is central to Alzheimer's disease (AD) pathology, impacting cognition and daily living.
  • Current AD pharmacotherapy primarily targets acetylcholinesterase (AChE) inhibition to address these deficits.
  • Severe AD exhibits significant reductions in AChE and choline acetyltransferase, with a concurrent increase in butyrylcholinesterase (BuChE).

Purpose of the Study:

  • To evaluate the potential therapeutic ceiling of existing AChE inhibitors in Alzheimer's disease.
  • To explore alternative and complementary cholinergic targets, including BuChE and nicotinic receptors.
  • To investigate combination drug strategies for managing Alzheimer's disease.

Main Methods:

  • Review of existing data on cholinergic function in Alzheimer's disease.

Related Experiment Videos

  • Analysis of the role of AChE and BuChE in AD pathology and senile plaques.
  • Exploration of novel drug development targeting AChE, BuChE, beta-amyloid, and nicotinic pathways.

    • Main Results:

    • AChE and BuChE are implicated in AD pathology, aggregating in senile plaques with beta-amyloid.
    • BuChE may represent a more suitable therapeutic target in severe AD due to increased levels.
    • Nicotinic receptor deficits suggest potential for new nicotinic drug development.

    Conclusions:

    • Current cholinergic therapies may have limitations, prompting exploration of alternative targets like BuChE.
    • Combined therapeutic mechanisms, potentially targeting AChE, BuChE, and beta-amyloid, show promise for AD treatment.
    • Developing ideal cholinergic inhibitors and combination therapies is crucial for advancing AD patient care.